Early pancreas transplant outcomes with histidine-tryptophan-ketoglutarate preservation: A multicenter study

被引:38
作者
Englesbe, Michael J.
Moyer, Alice
Kim, Dean Y.
Granger, Darla K.
Pietroski, Richard
Yoshida, Atsushi
Arenas, Juan D.
Oh, Henry
Pelletier, Shawn J.
Campbell, Darrell A., Jr.
Punch, Jeffrey D.
Magee, John C.
Gruber, Scott A.
Sung, Randall S.
机构
[1] Univ Michigan, Hlth Syst, Dept Surg, Div Transplantat, Ann Arbor, MI 48109 USA
[2] Henry Ford Hosp, Dept Surg, Div Transplantat, Detroit, MI 48202 USA
[3] St Johns Hosp, Dept Surg, Div Transplantat, Detroit, MI USA
[4] Gift Life Michigan, Ann Arbor, MI USA
[5] Wayne State Univ, Sch Med, Dept Surg, Sect Transplant Surg, Detroit, MI USA
关键词
complications of clinical transplantation; surgical; clinical transplantation; pancreas; histidine-tryptophan-ketoglutarate (HTK); organ preservation;
D O I
10.1097/01.tp.0000225764.21343.e3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Little is known about the use of histidine-tryptophan-ketoglutarate (HTK) preservation solution for pancreas preservation. We compared early pancreas graft outcomes at four pancreas transplant programs within the state of Michigan in 2002 and 2003 (University of Wisconsin [UW] era) with those in 2004 (HTK era). The primary endpoint was early graft loss. The UW group (n=41) and the HTK group (n=36) had similar outcomes with respect to: technical graft loss (9.8% vs. 8.3%, P=NS), 90-day graft function (90.2% vs. 86.1%, P=NS), and rate of pancreatic leak/abscess (12.2% vs. 11.1%, P=NS). There were also no significant differences in postoperative amylase and lipase levels between the two groups. The HTK group did have significantly more acute rejection within the first 180 days (25.0% vs. 9.8%, P < 0.05). HTK is a suitable substitute for UW in the preservation of pancreas allografts.
引用
收藏
页码:136 / 139
页数:4
相关论文
共 17 条
  • [1] Comparison of histidine-tryptophan ketoglutarate and University of Wisconsin solutions as primary preservation in renal allografts undergoing pulsatile perfusion
    Agarwal, A
    Goggins, WC
    Pescovitz, MD
    Milgrom, ML
    Murdock, P
    Fridell, JA
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (05) : 2016 - 2019
  • [2] Brandhorst H, 1995, TRANSPLANT P, V27, P3175
  • [3] MYOCARDIAL PROTECTION
    BRETSCHNEIDER, HJ
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 1980, 28 (05) : 295 - 302
  • [4] Canelo R, 2003, INT SURG, V88, P145
  • [5] Comparison of histidine-tryptophan-ketoglutarate solution and university of wisconsin solution for organ preservation in clinical pancreas transplantation
    Fridell, JA
    Agarwal, A
    Milgrom, ML
    Goggins, WC
    Murdock, P
    Pescovitz, MD
    [J]. TRANSPLANTATION, 2004, 77 (08) : 1304 - 1306
  • [6] Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching
    Gruber, SA
    Katz, S
    Kaplan, B
    Clark, JH
    Chen, PC
    El-Sabrout, R
    Kerman, RH
    [J]. TRANSPLANTATION, 2000, 70 (02) : 388 - 391
  • [7] GRUESSNER AC, 2001, CLIN TRANSPL, V41
  • [8] GRUESSNER AC, 2002, CLIN TRANSPL, V41
  • [9] Gruessner AC, 2003, CLIN TRANSPL, V21
  • [10] HTK-SOLUTION (BRETSCHNEIDER) FOR HUMAN LIVER-TRANSPLANTATION - 1ST CLINICAL-EXPERIENCES
    GUBERNATIS, G
    PICHLMAYR, R
    LAMESCH, P
    GROSSE, H
    BORNSCHEUER, A
    MEYER, HJ
    RINGE, B
    FARLE, M
    BRETSCHNEIDER, HJ
    [J]. LANGENBECKS ARCHIV FUR CHIRURGIE, 1990, 375 (02): : 66 - 70